X-linked severe combined immunodeficiency

GPTKB entity

Statements (50)
Predicate Object
gptkbp:instance_of gptkb:immunotherapy
gptkbp:affects immune system
gptkbp:associated_with increased susceptibility to infections
gptkbp:caused_by mutation in the IL2 RG gene
gptkbp:clinical_trial lymphopenia
ongoing for new therapies
absence of T and NK cells
focused on gene editing techniques
investigating alternative therapies
normal or elevated B cells
gptkbp:diagnosis newborn screening
gptkbp:diseases other forms of SCID
gptkbp:emergency_services IVIG therapy
immediate antibiotic therapy
gptkbp:financial_support resources for families
available through organizations
gptkbp:first_described_by in the 1960s
gptkbp:future_plans enhancing patient education
expanding access to treatments
improving gene therapy efficacy
gptkbp:gender_predominance male
gptkbp:genetic_studies recommended for families
available for IL2 RG gene
gptkbp:historical_context identified as a genetic disorder
part of the SCID spectrum
https://www.w3.org/2000/01/rdf-schema#label X-linked severe combined immunodeficiency
gptkbp:immunization_guidelines live vaccines contraindicated
inactivated vaccines recommended
gptkbp:inherits_from X-linked recessive
gptkbp:long_term_outcomes potential for normal life expectancy with treatment
improved with early treatment
risk of autoimmune diseases
gptkbp:prevalence 1 in 200,000 to 1 in 1,000,000 live births
gptkbp:public_awareness increased due to advocacy groups
gptkbp:research_focus gene therapy advancements
immunological studies
gptkbp:risk_factor maternal age
family history of SCID
gptkbp:screening_methods flow cytometry
PCR testing
gptkbp:symptoms failure to thrive
recurrent infections
gptkbp:transmission X-linked inheritance
gptkbp:treatment gptkb:gene_therapy
bone marrow transplant
access to specialized care
availability of donor matches
high cost of therapies
gptkbp:bfsParent gptkb:David_Vetter
gptkbp:bfsLayer 5